Warfarin Uses, Dosage, Side Effects & Warnings | DrugsAtlas
Authoritative Clinical Reference
Navigation
Therapeutic Class
Anticoagulant
Subclass
Vitamin K Antagonist (Coumarin derivative)
Speciality
Cardiology
Schedule (India)
Schedule H
Routes
Oral
Formulations
- Tablets: 1 mg, 2 mg, 3 mg, 5 mg
- Note: Not all strengths uniformly available across all pharmacies; 2.5 mg tablets available from select manufacturers
Adult indications
INDICATIONS + DOSING — FOR CLINICIAN USE ONLY
Primary Indications (Approved / Standard in India)
1. Venous Thromboembolism (VTE) — Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE)
| Parameter | Recommendation |
|---|---|
| Starting dose | 5 mg once daily for first 2 days; use 2–3 mg in elderly, hepatic impairment, malnutrition, or high bleeding risk |
| Overlap therapy | Initiate concurrently with LMWH/UFH; overlap for minimum 5 days AND until INR ≥2.0 for at least 24 hours |
| Titration | Adjust based on INR response; target INR 2.0–3.0 |
| Usual maintenance dose | 2–10 mg once daily (highly variable; INR-guided) |
| Maximum dose | No fixed maximum; dose determined by INR target |
Duration of Therapy:
| Scenario | Duration |
|---|---|
| First VTE provoked by transient risk factor | 3 months |
| First unprovoked VTE | 3–6 months minimum; consider extended therapy |
| Recurrent unprovoked VTE | Indefinite (lifelong) with annual bleeding risk reassessment |
| VTE with active malignancy | LMWH preferred; warfarin if LMWH not feasible — continue while cancer active |
2. Atrial Fibrillation (Valvular and Non-valvular)
| Parameter | Recommendation |
|---|---|
| Starting dose | 3–5 mg once daily; 2–3 mg in elderly or high-risk patients |
| Titration | Based on INR; check INR on day 3–5, then adjust |
| Target INR | 2.0–3.0 for most patients |
| Usual maintenance dose | INR-guided (typically 2–7 mg/day) |
| Maximum dose | Not applicable — INR-guided |
Clinical Notes:
- Use CHA₂DS₂-VASc score to determine need for anticoagulation
- Use HAS-BLED score for bleeding risk assessment annually
- Long-term/lifelong therapy in most cases
- Non-valvular AF: DOACs may be considered as alternative where appropriate
3. Mechanical Prosthetic Heart Valves
| Valve Position | Target INR | Additional Notes |
|---|---|---|
| Aortic valve (bileaflet/tilting disc, no risk factors) | 2.0–3.0 | Lower intensity acceptable in low-risk cases |
| Aortic valve with risk factors (AF, LV dysfunction, prior thromboembolism) | 2.5–3.5 | Add low-dose aspirin (75–100 mg) in high-risk |
| Mitral valve (any type) | 2.5–3.5 | Higher thrombogenic potential |
| Multiple valves or older generation valves | 2.5–3.5 | Consult cardiology |
| Parameter | Recommendation |
|---|---|
| Starting dose | 3–5 mg once daily |
| Titration | INR-guided; check frequently until stable |
| Usual maintenance dose | Individualised; typically 3–8 mg/day |
| Duration | Lifelong |
Clinical Notes:
- LMWH bridging required perioperatively
- DOACs are contraindicated in mechanical valves
- Regular dental prophylaxis advised
4. Rheumatic Mitral Valve Disease with Atrial Fibrillation
| Parameter | Recommendation |
|---|---|
| Starting dose | 3–5 mg once daily |
| Titration | INR-guided |
| Target INR | 2.0–3.0 |
| Usual maintenance dose | INR-guided |
| Duration | Long-term/lifelong |
Clinical Notes:
- Classified as valvular AF; DOACs not recommended
- Warfarin remains standard of care in India for rheumatic valvular disease
Secondary Indications — Adults (Off-label)
| Indication | Dose | Duration | Notes |
|---|---|---|---|
| Antiphospholipid Syndrome (APS) with thrombosis | Target INR 2.0–3.0 (standard); INR 3.0–4.0 in recurrent arterial events (controversial) | Lifelong |
OFF-LABEL — Specialist only; evidence from international guidelines and Indian rheumatology practice
|
| Cardioembolic Stroke (secondary prevention) | Target INR 2.0–3.0 | Long-term based on aetiology |
OFF-LABEL — Initiate 4–14 days post-stroke depending on infarct size and haemorrhagic transformation risk; specialist decision
|
| Left Ventricular Thrombus post-MI | Target INR 2.0–3.0 | 3–6 months or until thrombus resolution on imaging |
OFF-LABEL — Used in Indian cardiology practice; echocardiographic follow-up required
|
| Dilated Cardiomyopathy with severe LV dysfunction and AF/thrombus | Target INR 2.0–3.0 | Long-term |
OFF-LABEL — Specialist only
|
Paediatric indications
PAEDIATRIC DOSING (Specialist Only)
Primary Indications
Approved uses: Mechanical prosthetic heart valves, VTE treatment/prophylaxis, Fontan circulation, cardiac shunts, Kawasaki disease with coronary aneurysms
| Age Group | Starting Dose | Titration | Target INR | Monitoring |
|---|---|---|---|---|
| Neonates (<1 month) | 0.2 mg/kg once daily | Adjust based on INR; check day 2–3 | Indication-dependent | INR every 1–2 days initially |
| Infants/Children (1 month – 12 years) | 0.2 mg/kg once daily (max initial dose 5 mg) | Adjust based on INR | VTE: 2.0–3.0; Mechanical valve: 2.5–3.5 | INR every 2–3 days → weekly → monthly |
| Adolescents (>12 years) | 3–5 mg once daily (similar to adult) | INR-guided | As per indication | As per adult protocol |
INR Targets by Indication (Paediatric):
| Indication | Target INR |
|---|---|
| VTE (primary or secondary) | 2.0–3.0 |
| Mechanical mitral valve | 2.5–3.5 |
| Bioprosthetic valve (first 3 months) | 2.0–3.0 |
| Fontan/cavopulmonary shunt | 2.0–3.0 |
| Kawasaki with giant aneurysms | 2.0–3.0 (often with aspirin) |
Safety and Monitoring:
- Monitor INR every 2–3 days until stable, then every 1–2 weeks, then monthly
- Educate caregivers on bleeding signs, dietary consistency, drug interactions
- Vitamin K intake counselling essential
- Liquid formulations not commercially available; extemporaneous preparation may be needed
Secondary Indications — Paediatrics (Off-label)
| Indication | Dose | Duration | Notes |
|---|---|---|---|
| Antiphospholipid syndrome (paediatric) | 0.1–0.2 mg/kg/day; target INR 2.0–3.0 | Long-term |
OFF-LABEL — Specialist only; managed by paediatric rheumatology/haematology
|
| Catheter-related thrombosis (prolonged) | Weight-based; INR 2.0–3.0 | 3–6 months post catheter removal |
OFF-LABEL — Specialist only
|
Age Restriction Statement:
- NOT RECOMMENDED in neonates <1 month except under experienced paediatric haematology or cardiology specialist supervision
- Extreme caution required in preterm infants due to immature hepatic metabolism
Renal Adjustments
| Renal Function | Recommendation |
|---|---|
| Mild-moderate CKD (eGFR 30–60) | No specific dose adjustment; monitor INR more frequently due to increased bleeding risk |
| Severe CKD (eGFR <30) | Use with caution; increased bleeding tendency; INR may be less stable |
| ESRD / Haemodialysis | Warfarin is NOT dialysed; can be used in dialysis patients with mechanical valves or valvular AF; preferred over DOACs in this population |
| Peritoneal dialysis | No adjustment; INR monitoring as usual |
Clinical Note: Warfarin preferred over DOACs in patients with eGFR <15 mL/min or on dialysis requiring anticoagulation for valvular indications.
Hepatic adjustment
Contraindications
- Active clinically significant bleeding (GI, intracranial, retroperitoneal, etc.)
- Haemorrhagic stroke (recent or ongoing)
- Severe uncontrolled hypertension (>180/110 mmHg)
- Pregnancy — 1st trimester (teratogenic) and last 4 weeks (delivery-related bleeding risk)
- Known hypersensitivity to warfarin or any coumarin derivative
- Inability to monitor INR reliably (non-compliance, remote access issues)
- Severe thrombocytopenia (<50,000/μL)
- Recent or planned neurosurgical, ophthalmic, or spinal procedures (within 72 hours)
- Unsupervised alcoholism with poor compliance
Cautions
- Hepatic disease — enhanced anticoagulant effect
- Malnutrition or vitamin K deficiency — increased sensitivity
- Congestive heart failure — may affect hepatic metabolism
- Hyperthyroidism — increases warfarin catabolism of clotting factors; may need dose adjustment
- Elderly with fall risk — increased intracranial bleeding risk
- Recent surgery or trauma
- Active peptic ulcer disease (even if not currently bleeding)
- Polypharmacy — multiple drug interactions affecting INR
- Inconsistent dietary vitamin K intake
- Diarrhoeal illness — may alter vitamin K absorption and warfarin effect
- Protein C or S deficiency — risk of warfarin-induced skin necrosis at initiation; bridge with heparin
Pregnancy
| Aspect | Recommendation |
|---|---|
| Risk category |
Contraindicated in 1st trimester and near term (Risk category: D/X depending on timing)
|
| Fetal risks | 1st trimester: Fetal warfarin syndrome (nasal hypoplasia, stippled epiphyses, limb hypoplasia, CNS abnormalities) — risk 5–10% with exposure weeks 6–12 |
| 2nd–3rd trimester risks | Fetal/neonatal haemorrhage, CNS abnormalities |
| Preferred alternatives | LMWH (enoxaparin) throughout pregnancy in most cases |
| When warfarin may be used | High-risk mechanical heart valves where LMWH deemed inadequate — specialist decision only; typically 2nd trimester with LMWH in 1st trimester and last 4 weeks |
| Monitoring | Fetal anatomy scan at 18–22 weeks, serial growth scans, maternal INR, delivery planning with haematology/cardiology |
Lactation
| Aspect | Recommendation |
|---|---|
| Compatibility |
Compatible with breastfeeding
|
| Drug levels in milk | Minimal/negligible — warfarin is highly protein-bound; transfer to breast milk is clinically insignificant |
| Preferred alternatives | Not required; warfarin is considered safe |
| Infant monitoring | Routine observation; monitor for unusual bruising or bleeding only if mother's INR is significantly supratherapeutic |
Elderly
| Aspect | Recommendation |
|---|---|
| Starting dose | 2–3 mg once daily (lower than standard adult dose) |
| Titration | Slower; assess INR more frequently (every 2–3 days initially) |
| Usual maintenance | Often lower than younger adults (typically 2–5 mg/day) |
| Special risks | Increased bleeding risk (falls, GI bleed, intracranial haemorrhage); polypharmacy; impaired renal function; cognitive impairment affecting compliance |
| Recommendations | Fall risk assessment; medication reconciliation; caregiver education; consider pill organizers; frequent INR checks |
Major drug interactions
| Drug/Class | Effect on Warfarin/INR | Mechanism | Management |
|---|---|---|---|
| Rifampicin | ↓↓ INR (marked reduction) | Potent CYP2C9/CYP3A4 inducer | Avoid combination; if essential, increase warfarin dose significantly (may need 2–3x); monitor INR frequently |
| Phenytoin, Carbamazepine, Phenobarbital | ↓ INR | CYP inducers | Monitor INR; dose adjustment required |
| Amiodarone | ↑↑ INR (marked increase) | CYP2C9 inhibition | Reduce warfarin dose by 30–50% when adding amiodarone; monitor INR weekly for 4–6 weeks |
| Fluconazole, Voriconazole, Ketoconazole | ↑↑ INR | CYP2C9 inhibition | Reduce warfarin dose; frequent INR monitoring |
| Metronidazole | ↑ INR | CYP inhibition | Reduce dose or use short course with monitoring |
| NSAIDs (regular use) | ↑ Bleeding risk | Platelet inhibition + possible GI erosion | Avoid chronic use; if needed, use lowest dose with PPI cover and closer INR monitoring |
| Aspirin (>100 mg/day) | ↑ Bleeding risk | Additive antiplatelet effect | Avoid unless specific indication (e.g., mechanical valve with high risk) |
| Cotrimoxazole (TMP-SMX) | ↑ INR | CYP2C9 inhibition | Reduce warfarin; monitor closely |
Moderate drug interactions
| Drug/Class | Effect | Management |
|---|---|---|
| Macrolides (Erythromycin, Clarithromycin, Azithromycin) | ↑ INR | Monitor INR during antibiotic course; may need dose reduction |
| Fluoroquinolones (Ciprofloxacin, Levofloxacin) | ↑ INR | Monitor INR; reduce warfarin if needed |
| Cephalosporins (especially cefoperazone, ceftriaxone) | ↑ INR | Vitamin K depletion; monitor INR |
| Paracetamol (>2 g/day regularly) | ↑ INR (modest) | Monitor INR with chronic high-dose use |
| Levothyroxine | ↑ Warfarin effect | Potentiates vitamin K-dependent factor catabolism; monitor INR after thyroid dose changes |
| SSRIs (Fluoxetine, Sertraline) | ↑ Bleeding risk | Platelet dysfunction + possible CYP interaction; monitor for bleeding signs |
| Statins (some) | Variable; usually modest ↑ INR | Monitor INR when initiating or changing statin |
| Omeprazole | ↑ INR (modest) | CYP2C19 interaction; usually minor; monitor |
| Herbal products (Garlic, Ginkgo, Ginger, Ginseng) | Variable INR effects | Counsel patients to maintain consistent intake; inform physician before use |
| Cranberry juice (large quantities) | ↑ INR | Avoid excessive consumption |
Common Adverse effects
- Bleeding (minor) — gum bleeding, epistaxis, easy bruising, prolonged bleeding from cuts
- Haematuria (microscopic or gross)
- Menorrhagia
- Nausea, vomiting
- Diarrhoea or abdominal discomfort
- Alopecia (with prolonged use)
- Skin rash
Serious Adverse effects
| Adverse Effect | Clinical Features | Management |
|---|---|---|
| Major haemorrhage (GI, intracranial, retroperitoneal) | Haematemesis, melaena, altered sensorium, severe headache, haematochezia, hypotension |
Immediate cessation; IV Vitamin K 5–10 mg slow infusion; 4-factor PCC (preferred) or FFP; ICU admission; surgical intervention if indicated
|
| Warfarin-induced skin necrosis | Painful purpuric skin lesions → necrosis; occurs days 3–8 of therapy; more common in protein C/S deficiency |
Stop warfarin immediately; heparinisation; vitamin K; specialist dermatology/haematology input; may require debridement
|
| Purple toe syndrome | Painful, purple discolouration of toes; cholesterol microembolism | Discontinue warfarin; supportive care |
| Calciphylaxis (rare, in CKD patients) | Painful, necrotic skin lesions | Stop warfarin; specialist nephrology input |
| Fetal warfarin syndrome | Nasal hypoplasia, skeletal abnormalities | Prevention — avoid in pregnancy |
Monitoring requirements
| Timing | Parameters |
|---|---|
| Baseline (before initiation) | PT/INR, aPTT, complete blood count, liver function tests, renal function, bleeding history assessment |
| After initiation | INR on day 2–3, day 5, then every 2–3 days until stable within therapeutic range |
| After dose adjustment | INR within 3–5 days of any dose change |
| Stable long-term therapy | INR every 2–4 weeks (depending on stability); at least monthly |
| Additional monitoring | Haemoglobin (periodically), signs of bleeding, medication reconciliation at each visit, dietary vitamin K consistency |
INR Interpretation and Action:
| INR Value | Action |
|---|---|
| <1.5 | Increase dose; reassess compliance, diet, interactions |
| 1.5–1.9 | Increase dose modestly |
| 2.0–3.0 (or target range) | Therapeutic; continue same dose |
| 3.1–4.0 | Reduce dose; recheck in 1 week; assess for bleeding |
| 4.1–5.0 | Hold 1 dose; reduce subsequent doses; recheck in 2–3 days |
| 5.1–9.0 (no bleeding) | Hold warfarin; oral Vitamin K 1–2.5 mg if high bleeding risk; recheck daily |
| >9.0 (no bleeding) | Hold warfarin; oral Vitamin K 2.5–5 mg; recheck in 24–48 hours |
| Any INR with serious bleeding | Stop warfarin; IV Vitamin K 5–10 mg; 4-factor PCC or FFP; hospital admission |
Brands in India
Warfarin Sodium Brands:
- Warf (Cipla)
- Sofarin (Samarth Pharma)
- Uniwarfin (Unichem)
- Marevan (Aspen — limited availability)
- Warfarin (generic — various manufacturers)
Note:
- Acitrom® contains acenocoumarol (NOT warfarin) — different VKA with shorter half-life
- Do NOT interchange warfarin with acenocoumarol without re-titration of INR; different dosing and kinetics
Price range (INR)
| Formulation | Approximate Price |
|---|---|
| Warfarin 1 mg tablet | ₹1–2 per tablet |
| Warfarin 2 mg tablet | ₹1.50–2.50 per tablet |
| Warfarin 5 mg tablet | ₹2–4 per tablet |
Notes:
- Significantly cheaper than DOACs
- Not included in NLEM 2022 (acenocoumarol is listed instead)
- Available in government hospitals in most states
- No NPPA price ceiling applicable
Clinical pearls
- Always check baseline INR before initiating warfarin — do not assume it is normal, especially in liver disease or malnutrition.
- LMWH bridging is mandatory at initiation — warfarin takes 4–5 days to achieve anticoagulant effect; continue LMWH until INR ≥2.0 for at least 24 hours on two consecutive measurements.
- Dietary vitamin K counselling is essential — advise consistent (not restricted) intake of green leafy vegetables; erratic dietary changes cause INR fluctuations.
- Do NOT switch between warfarin and acenocoumarol casually — different pharmacokinetics require complete INR re-stabilisation.
- INR >10 without bleeding — give oral Vitamin K 2.5–5 mg and hold warfarin; do not panic or give high-dose IV vitamin K unless actively bleeding.
- Perioperative management — for elective surgery, stop warfarin 5 days prior; bridge with LMWH if high thrombotic risk (mechanical valves, recent VTE); resume post-op when haemostasis secured.
Version
RxIndia v1.1 — 13 Jun 2025
Reference
- CDSCO-approved prescribing information
- Indian Pharmacopoeia 2022
- API Textbook of Medicine (11th Edition)
- AIIMS Anticoagulation Protocols
- MoHFW NCD Guidelines — Atrial Fibrillation
- ICMR Guidelines on Cardiovascular Disease Management
- Harrison's Principles of Internal Medicine (21st Edition)
- ACC/AHA Guidelines (for international reference where not conflicting with Indian practice)
- NLEM 2022 (reference: acenocoumarol listed; warfarin in public hospital formularies)
- Indian Society of Haematology and Blood Transfusion protocols
⚖️
Clinical Responsibility
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.